Participated · Equity · Mar 2026

Primio has built a mobile-first learning and work platform designed for the many practically schooled employees and informal caregivers who support the Dutch elderly-care system. The app hosts more than 80 visual, bite-sized trainings—co-created with care organisations—covering topics such as early-warning signs, ergonomic working and mental resilience. Lessons last only a few minutes, fit easily into the workday and aim to drive measurable behavioural change; the company now issues over 750 certificates per week, cuts learning time by 75 %, and reports 82 % fewer physical and mental complaints after three months of ergonomic training. User satisfaction scores average 4.3/5 across more than 107,000 evaluations, and participants report a 40 % increase in perceived support. Primio’s founders aim to reach 100 million certificates in the Netherlands and internationally, thereby easing pressure on district nursing and nursing-home care. The freshly raised capital will fund further product development and expansion to additional Dutch care organisations. Prior backers include Healthy.Capital, though historic round sizes were not disclosed.

Participated · Series A · Jul 2025

Plasmacure is a Nijmegen-based MedTech company whose flagship product, PLASOMA, applies cold plasma directly to complex wounds to accelerate healing. The PLASOMA pulser delivers controlled electric pulses to a disposable pad, generating cold plasma at the wound that acts as a potent antimicrobial and stimulates blood flow and cell regeneration. The company reports a randomized controlled trial in which PLASOMA closed up to 2.5 times more complex wounds than standard care. Plasmacure plans to scale globally and advance adoption of PLASOMA for indications including diabetic foot ulcers, venous leg ulcers, and pressure ulcers. To support expansion, the company announced a €6 million Series A and secured additional financing for U.S. regulatory and reimbursement pathways. Management frames the financing as enabling a U.S. rollout and broader global commercialization.